Scotiabank Forecasts Strong Price Appreciation for Beam Therapeutics (NASDAQ:BEAM) Stock
Beam Therapeutics (NASDAQ:BEAM – Get Free Report) had its price objective hoisted by investment analysts at Scotiabank from $24.00 to $25.00 in a report issued on Monday,Benzinga reports. The firm presently has a “sector perform” rating on the stock. Scotiabank’s target price would suggest a potential downside of 5.45% from the stock’s current price. A […]
Beam Therapeutics (NASDAQ:BEAM – Get Free Report) had its price objective hoisted by investment analysts at Scotiabank from $24.00 to $25.00 in a report issued on Monday,Benzinga reports. The firm presently has a “sector perform” rating on the stock. Scotiabank’s target price would suggest a potential downside of 5.45% from the stock’s current price. A […]
